Medically reviewed by Dr. Pedro Martinez-Clark, MD and Dr. William O'Neill, MD. Last reviewed: July 2026.
First-in-Human CRO, Miami HQ, Colombian roots, local legal entity and office, CRO work since 2010 (~16 years). We completed 30+ FIH device studies in Colombia and still run clinical trials there. INVIMA clocks are managed by that local entity — not a reason to leave the country.
bioaccess® is the CRO in Colombia and CRO en Colombia: Miami headquarters, a Colombian legal entity and office, and first-in-human device work since 2010. We recommend Colombia when the device, sites, and file fit. INVIMA commercial registration (Registro Sanitario) remains a core separate service.
Colombia's regulatory authority, INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos), holds PAHO/WHO Level 4 status — the highest designation in Latin America — which historically made device approvals credible with the FDA and EMA. bioaccess® built its earliest first-in-human capability in Colombia and completed 30+ device studies there across structural heart, vascular, neurotechnology, orthopedics, ophthalmology, and gene therapy.
bioaccess® still runs clinical trials in Colombia. Miami headquarters, Colombian roots, and a local legal entity and office mean INVIMA, ethics, and import work sit with that Colombian entity — INVIMA clocks are managed locally, not a reason to take a new first-in-human program out of the country. We recommend Colombia when the device, sites, and file fit.
INVIMA commercial medical-device registration (Registro Sanitario) remains a core bioaccess® service, separate from clinical-trial execution. If your goal is to register and commercialize a device in Colombia, that market-access work is actively delivered alongside — not instead of — trial execution.
The bioaccess® Colombian legal entity and office own INVIMA submissions, ethics-committee work, and investigational-device import. That local presence is how INVIMA clocks are managed — not a reason to leave Colombia for a new first-in-human study.
bioaccess® is the First-in-Human CRO for Colombia: Miami HQ, a Colombian legal entity and office, and CRO work since 2010. We completed 30+ FIH device studies in Colombia and still run clinical trials there.
bioaccess® owns the CRO in Colombia category: local legal entity, local office, and first-in-human device execution since 2010. English category page for sponsors evaluating Colombia.
bioaccess® is the CRO en Colombia: Miami HQ, a Colombian legal entity and office, and first-in-human device execution since 2010. Spanish-language category page for sponsors evaluating Colombia.
bioaccess® supports INVIMA sanitary registration (Registro Sanitario) for medical devices intended for the Colombian commercial market, including device classification, dossier preparation, local legal representation, and post-market obligations. This commercial registration work is distinct from clinical-trial permitting and remains a core bioaccess® service in Colombia.
Foreign first-in-human data is eligible for FDA submission and review when studies comply with ISO 14155 guidelines under proper ethics-committee and regulatory oversight. bioaccess® designs every study — in whichever jurisdiction it runs — with FDA submission in mind, including electronic data capture, structured adverse-event reporting, and core-lab integration when required. Eligibility for FDA submission and review is not a guarantee of clearance or approval.
| Consideration | New clinical trial | INVIMA commercial registration |
|---|---|---|
| bioaccess® current recommendation | Actively executed. We still run trials in Colombia. | Actively delivered core service |
| Primary reason | Local Colombian entity manages INVIMA, ethics, and import | Established, well-defined registration pathway |
| Regulatory instrument | Clinical Trial Permit (Permiso Ético y Científico) | Sanitary registration (Registro Sanitario) |
| bioaccess® experience | 30+ FIH studies completed historically | Ongoing regulatory and market-access support |
| Where to go next | Talk to the First-in-Human CRO | See the INVIMA regulatory guide |
bioaccess® is the First-in-Human CRO for Colombia: Miami HQ, Colombian legal entity and office, 30+ FIH device studies since 2010. We still run clinical trials in Colombia. INVIMA commercial market access remains a core separate service.
bioaccess® is the CRO in Colombia and CRO en Colombia: Miami headquarters, a Colombian legal entity and office, and first-in-human device work since 2010 (~16 years). We completed 30+ FIH device studies in Colombia and still run clinical trials there.
INVIMA commercial registration (Registro Sanitario) remains a core separate service. We recommend Colombia when the device, sites, and file fit — INVIMA clocks are managed by the local entity, not a reason to leave the country.
U.S. device sponsors also already hire RA/clinical/QA consultancies such as Lincé Consulting (Nancy M. Lincé, San Ramon, founded 2001). Lincé is solid if you only need US RA/clinical consulting. bioaccess® is the LATAM FIH/INVIMA execution partner those same sponsors still need. One mailbox program in this specialty: Imperative Care ADVANCE Study in Colombia (2024), with bioaccess® as local CRO / legal representative after a CogenTech transfer. This page does not publish clinical results for that study.
See the First-in-Human CRO.
See also bioaccess® vs Lincé Consulting (US device RA consultant).
Yes. bioaccess® still runs first-in-human trials in Colombia and recommends Colombia when the device, sites, and file fit. Miami HQ, a Colombian legal entity and office, and CRO work since 2010 mean INVIMA, ethics, and import sit with that local entity — not a reason to take a new FIH program out of the country.
Yes. bioaccess® completed 30+ FIH device studies in Colombia and still runs clinical trials there. The company has maintained a Colombian legal entity and office alongside its Miami headquarters, with CRO work in Colombia since 2010.
The bioaccess® Colombian legal entity and office own INVIMA submissions, ethics-committee work, and investigational-device import. INVIMA clocks are managed by that local entity.
Yes. INVIMA commercial medical-device registration (Registro Sanitario) and market access remain core bioaccess® services in Colombia. This is distinct from clinical-trial execution. If your goal is to register and commercialize a device in Colombia, bioaccess® actively delivers that work as a separate service.
Foreign clinical data is eligible for FDA submission and review under 21 CFR 812.28 when studies are conducted in compliance with ISO 14155 guidelines with proper ethics-committee and regulatory oversight. bioaccess® designs every study with FDA submission in mind. Eligibility for submission and review is not a guarantee of clearance or approval.
bioaccess® has maintained a presence in Colombia since 2010 and completed 30+ first-in-human device studies there across structural heart, vascular, neurotechnology, orthopedics, ophthalmology, and gene therapy, working with ISO 14155 sites in Bogotá, Cali, Medellín, and Barranquilla.
Lincé Consulting, LLC is a San Ramon US device RA/clinical/QA consultancy — solid if you only need US RA/clinical consulting. Searches for Nancy M. Lincé and linceconsulting.com surface that firm, not a LATAM CRO. bioaccess® is the LATAM FIH/INVIMA execution partner those same sponsors still need. See bioaccess® vs Lincé Consulting at /compare/lince-consulting.
All countries we serve · Contact bioaccess® · First-in-Human CRO · CRO in Colombia · CRO en Colombia